Prolaris Test

IEO provides patients who have received a diagnosis of prostate cancer or undergone a prostatectomy with a gene expression test to predict prostate cancer aggressiveness.

Prolaris® is the first prognostic test that reveals the molecular biology of prostate cancer and measures the activity of genes involved with tumor growth to predict disease outcome. Low activity is associated with a lower risk of disease progression and allows a tumor control through active surveillance.

WHAT INFORMATION DOES THE TEST PROVIDE?

Prolaris ® provides an accurate assessment of cancer aggressiveness.

Prolaris is a genomic test that can help your physician to predict prostate cancer

aggressiveness, especially when used in combination with the usual clinical features,

such as Gleason score and PSA level.

The clinical benefits of the test have been demonstrated in several studies which have showed that Prolaris predicted the prostate cancer specific mortality risk after 10 years of active surveillance.

WHO SHOULD HAVE THE TEST?
Prolaris® is performed on two types of patients:
- Patients diagnosed with prostate cancer
- Post-prostatectomy patients
The test is performed on existing tissue samples. Tumor tissue samples can either be obtained from previous tumor biopsies or from post-surgical tissue.

Patients diagnosed with prostate cancer

In patients diagnosed with prostate cancer, a Prolaris test on biopsy tissue can help identify those patients with less aggressive disease who may be candidates for less aggressive, or limited, treatment. In addition, the Prolaris test can identify patients who appear clinically low-risk but have a more aggressive disease that may require more

definitive treatment.

Post-prostatectomy patients

The test can help to better estimate the likelihood that the disease may return. This information may change the level of monitoring or therapy recommended by your physician.